Disc Medicine (NASDAQ:IRON) Rating Reiterated by Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Disc Medicine (NASDAQ:IRON – Free Report) in a research report sent to investors on Wednesday, Benzinga reports. They currently have a $85.00 price objective on the stock. Other research analysts also recently issued reports about the company. Wedbush reiterated an outperform rating and issued a $79.00 […]

Leave a Reply

Your email address will not be published.

Previous post StockNews.com Begins Coverage on Lipocine (NASDAQ:LPCN)
Next post Timberwolves use ‘complete performance on both ends’ to down Kings in Sacramento